To influence policy on critical issues like the Priority Review Voucher, biotech CEOs are forming consortiums and going to Washington as a unified group. This collaborative approach is more effective than individual company efforts because it demonstrates a widespread industry problem that needs a legislative solution.

A significant disconnect exists between the FDA leadership's public statements promoting flexibility and the stringent, delay-prone reality faced by companies. For areas like gene therapy, firms report feeling the "rug was pulled out," suggesting investors should be skeptical of the agency's accommodating PR.

The FDA publicly promotes regulatory flexibility for rare diseases, yet industry insiders perceive it as less permissive than prior administrations. This disconnect between the agency's messaging and its actual decisions is fueling widespread criticism, investor uncertainty, and accusations of 'moving the goalposts'.

When CEOs face pressure to speak on political issues, acting as a unified group, like the 69 Minnesota CEOs did, provides safety in numbers. A coalition is harder for political actors to single out and punish than an individual executive.

Biotech companies are intensely reliant on the FDA for approvals, making it nearly impossible to enforce legal agreements or challenge the agency publicly, even when wronged. This "repeat relationship" means the FDA ultimately holds all the power, making any direct conflict a perilous decision for a company.

The current political and regulatory environment means running a biotech company is no longer just about science and capital. CEOs must now actively engage in policy discussions and lobby legislators to ensure the ecosystem remains favorable for innovation. Ignoring politics is no longer an option.

Bio is creating a formal system for biotech companies to report challenges with the FDA. Bio will synthesize this feedback monthly and present it directly to FDA leadership, creating a novel channel to elevate systemic issues and improve accountability.

Stelios Papadopoulos claims the biotech industry's public silence on the FDA's dysfunction stems from two core factors: a rational fear of agency retribution against their companies, and a passive hope that future political changes will magically resolve the issues.

Industry sentiment on the FDA is not monolithic. A recent survey reveals that while biotechs largely maintain confidence in the agency's hardworking staff and their day-to-day interactions, there is deep concern and a lack of trust in the agency's top leadership. This nuanced view highlights that the perceived problems are rooted in politicization and leadership competence, not frontline operations.